Medicines Co. Stock

On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.

According to

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade.

According to a SEC

Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines

More often than not, takeover speculation can give a lively boost -- at least in the short term -- to a company's stock. That was the dynamic behind the nearly 11% price gain of Revolution Medicines

Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical company received a Breakthrough Therapy Designation (BTD) for its experimental tremor

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can